FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:1023-1024 April 3, 1997 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Packer, M. PubMed Citation

To the Editor: When the findings of a clinical trial are diametrically the opposite of those anticipated, a reevaluation of the original premises of the study is appropriate. Packer et al. (Oct. 10 issue)¹ reported that amlodipine reduced mortality in a subgroup of patients with "nonischemic dilated cardiomyopathy." No satisfactory explanation was provided for this unexpected result.

The use of the phrase "nonischemic dilated cardiomyopathy" suggests that the investigators considered that condition to be almost synonymous with idiopathic dilated cardiomyopathy, in which the coronary angiogram is normal. The proportion of patients in the trial classified as having "nonischemic dilated cardiomyopathy" . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Follath, F., Cleland, J. G. F., Klein, W., Murphy, R. (1998). Etiology and response to drug treatment in heart failure. J Am Coll Cardiol 32: 1167-1172 [Abstract] [Full Text]  
• Kribbs, S. B., Merritt, W. M., Clair, M. J., Krombach, R. S., Houck, W. V., Dodd, M. G., Mukherjee, R., Spinale, F. G. (1998). Amlodipine Monotherapy, Angiotensin-Converting Enzyme Inhibition, and Combination Therapy With Pacing-Induced Heart Failure. Hypertension 31: 755-765 [Abstract] [Full Text]